Biomarkers used in clinical practice for treatment stratification are, e.g., the human epidermal growth factor receptor 2 (HER-2) status for breast cancer patients [9, 10] or presence of epidermal growth factor receptor (EGFR) mutation in non-small cell lung cancers (NSCLC) [11]. This evidence concerns the gene EGFR and breast carcinoma.